Background and Aims:
Introduction
Inhibition of lymphocyte trafficking from blood vessels into tissue offers the promise of treatment for a variety of inflammatory diseases. Lymphocyte trafficking is a complex process that is mediated in part by binding of integrins, such as LFA-1 and α4β7, to cell adhesion molecules, such as ICAM-1 and VCAM-1.
1,2 However, this category of drugs has significantly lost momentum due to the high incidence of progressive multifocal leukoencephalopathy [PML] . The first two anti-integrin agents reported to inhibit lymphocyte traffick- . [6] [7] [8] The mechanism by which natalizumab is thought to cause PML includes diminished CNS immune surveillance due to inhibition of the α 4 β 1 -VCAM-1 pathway. 9 In patients treated with natalizumab, three clinical risk factors for PML have been identified: 1] treatment duration [ie, 25-48 months] ; 2] previous exposure to JCV, measured by the presence of anti-JCV antibodies; and 3] history of previous immunosuppressant therapy. More than 1% of patients who had all three risk factors developed PML. 10 Analysis of cerebrospinal fluid [CSF] from patients with MS as early as 6 weeks after the first dose of natalizumab showed a reduction in CD4+ T cell count and inversion of the CD4:CD8 ratio, a finding consistent with impaired immune surveillance. 11 As a result, therapies with greater selectivity have been developed especially for inflammatory bowel disease [IBD] , in the belief that they would reduce or eliminate the risk of PML while maintaining anti-inflammatory potency in the gut. 12 Crohn's disease is a relapsing systemic IBD that mainly affects the gastrointestinal [GI] tract; it is triggered by environmental factors in genetically susceptible individuals, resulting in a disturbed mucosal immune response leading to chronic ulcerations in the GI tract. 13 A key feature of this inflammatory process is transmural inflammation, with a massive presence of leukocytes recruited from the circulation into the gut mucosa. 14 Interference with mechanisms regulating lymphocyte adhesion and trafficking into inflamed gut tissue is an attractive target for therapeutic intervention. 15 The integrin α 4 β 7 mediates the homing of memory T cells to the intestinal mucosa via binding to its endothelial ligand, MAdCAM-1. 10, 16 MAdCAM-1 is upregulated in the presence of inflammation and is expressed at high levels on high endothelial venules in gut and gut-associated lymphoid tissue of patients with IBD. 17 Although it can also be induced by inflammation, 18 MAdCAM-1 is not constitutively expressed in the CNS
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; therefore, drugs that selectively target this translocation axis may reduce inflammation in the gut without affecting immune surveillance in the CNS.
PF-00547659 is a human monoclonal antibody that binds selectively and with high affinity to mouse and human MAdCAM-1; it potently inhibits adhesion of α 4 β 7 + leukocytes to MAdCAM-1, while having no effect on the adhesion of α 4 β 1 to VCAM-1. 20 The purpose of our study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active CD and a history of immunosuppressive therapy.
Methods

Study design
The study was executed in three parts under two protocols [ Figure 1 The presence of active CD was confirmed by endoscopy that showed mucosal ulceration > 0.5 cm, cobblestoning, or at least five aphthous ulcers-documented by photograph. Patients with stomas were included if they demonstrated active disease on endoscopy or appropriate imaging, eg. computed tomography/magnetic resonance enterography. Those who were receiving therapy with azathioprine, 6-mercaptopurine, or methotrexate were allowed to enter the study provided they terminated such therapy between Weeks 8 and 12 of the study. We permitted stable doses of prednisolone ≤ 20 mg/day or equivalent oral systemic corticosteroid dose, or oral budesonide ≤ 6 mg/day.
Lumbar puncture and CSF
Patients who met inclusion criteria underwent LP using a 22G 90-mm atraumatic spinal anaesthesia needle with introducer [http:// www.imd-inc.com/spinalanesthesia.php]. In healthy volunteers, 10 mL of CSF were withdrawn and preserved in TransFix ® . In patients with CD, 14 mL of CSF were withdrawn; 10 mL preserved with TransFix ® were transferred to a central laboratory for flow cytometry; 3 mL were analysed at the local laboratory for culture, protein, glucose, and cell count; and 1 mL was evaluated for JCV DNA and anti-JCV antibody.
Study drug
PF-00547659 was administered by subcutaneous injection every 4 weeks. The 225-mg dose was selected as the highest repeated dose given in the Phase I trial. 21 
Study visits
Healthy volunteers had a single visit. Patients with CD returned every 4 weeks for treatment, assessment of disease activity with HBI, 22 evaluation of adverse events, physical examination, electrocardiogram [ECG], and laboratory tests. All patients who underwent the first LP were permitted to receive the study drug. At each LP visit, venous blood was also withdrawn for analysis by flow cytometry. In Cohort 1, the second LP was performed before the administration of the study drug and 14 ± 4 days after the first LP. In Cohort 2, the second LP was performed 2 ± 1 weeks after the latest dose of study drug [ie. at Week 9-11 after baseline]. The final study visit was performed 4 weeks after the third dose of study drug, at which time patients who had a clinical response to the study drug were allowed to enrol in an open-label extension study.
Study endpoints
The primary endpoint was the percentage change in absolute lymphocyte count in the CSF of patients with CD after receiving three monthly doses of PF-00547659. Secondary endpoints included clinical response (defined as a reduction in disease activity [HBI score] from baseline by ≥ 3 points) and remission [defined as an HBI score < 5 points]. Additional analyses included characterisation of lymphocyte subpopulations in both CSF and blood before and after treatment with PF-00547659. Completed pilot n=10
Discontinued n=3
Currently under evaluation n=2
Received treatment n=39
Completed treatment n=38 Underwent lumbar punctures n=38
Completed study n=34 
Study oversight
The protocol for this study was developed by the authors and approved by ethics committees and, where appropriate, national or regional authorities. A data-monitoring committee adjudicated any patients with unexplained neurological findings or suspected potential PML. All authors had full access to all data. All the authors reviewed and approved the final manuscript, and made the decision to submit the manuscript for publication and all vouch for the veracity and completeness of the data, the analyses and the fidelity of the study to the protocol.
Statistical analysis
The analysis was designed to show that the percentage decrease from baseline in absolute lymphocyte count in CSF is < For results to be deemed statistically significant, the 10% lower confidence limit of the percentage decrease from baseline of the GMR had to be > 0.5. The data reported were obtained from a cleaned locked database for inclusion in this manuscript.
Results
As shown in 
Pre-interventional CSF characteristics─cohort 1
In patients with CD, the numbers of lymphocytes and lymphocyte subpopulations were within published reference ranges. 23, 24 Pretreatment CSF lymphocyte and lymphocyte subset counts were similar between LP 1 and 2 for most patients evaluated in Cohort 1 [Supplementary Table S2 and Supplementary Figure S2, 
Effects of PF-00547659─Cohort 2
Immunological effects
After treatment, there was a small increase in the numbers of overall CSF lymphocytes across several subsets [CD3+; CD4+; CD8+]; the CD4:CD8 ratio was similar before and after treatment [ Figure 2 ; Supplementary Table S3, available at ECCO-JCC online]. Among the nine patients who continued to receive immunosuppressant therapy during the study, baseline numbers of T-lymphocytes and subsets were about 20% lower than in the other 28 patients, but the differences were neither significant nor below the range seen in healthy volunteers [ Table 1 ]. Concurrent use of systemic glucocorticoids was associated with lower pre-treatment CSF CD4+, but not CDF8+ T-lymphocytes, in a dose-related manner [data not shown].
CSF CD4:CD8 ratios were similar both before and after treatment, and in patients receiving or not receiving concomitant immunosuppressants. As in healthy subjects, very few NK and B cells were seen. Post-treatment changes were similar in magnitude regardless of ongoing immunosuppressant treatment [ Table 2 ]. No JCV DNA was detected in 20 pre-treatment or 19 post-treatment samples of CSF.
In peripheral blood, the only change associated with PF-00547659 treatment was a 1.45-fold mean increase [90% CI: 1.31, 1.61] in β7+ central memory T-lymphocytes between baseline Table S5, available as Supplementary data at ECCO-JCC online]. The improvement in this partial HBI was similar in patients with intact GI tracts and those with stomas. The only disease biomarker assessed was hs-CRP, the geometric mean value for which decreased 29.8% in all patients.
Safety
Treatment-emergent adverse events were reported by 46 [94%] patients. No patient withdrew from the study due to an adverse event. The most common adverse events are listed in Table 4 ; 23 patients had adverse events considered related to study treatment, including four injection-site reactions. The most common events considered related to study treatment were arthralgia and nasopharyngitis, reported in four patients each. One patient who did not experience clinical response discontinued from the study; two other patients withdrew consent; and one was lost to follow-up. Five serious adverse events [SAEs] were reported in four patients. One had enterocutaneous fistula and fatigue, one had nephrolithiasis and two patients reported exacerbations of CD. All events resolved and none was considered to be related to study treatment.
Clinical laboratory parameters
None of the laboratory abnormalities was reported as an AE by the investigators. No significant elevations in liver tests were observed [ie. bilirubin was always < 2 × ULN and transaminases were always < 3 × ULN], and no cases met the criteria of Hy's Law.
Discussion
The selective anti-MAdCAM monoclonal antibody PF-00547659 was developed to mitigate the risk of PML seen with natalizumab. We hypothesised that its lack of binding to VCAM-1 would result in preserved lymphocyte translocation into the CSF, thereby minimising the risk of PML. Of the known risk factors for PML in natalizumab-treated patients, 10 only the mechanism by which previous immunosuppressant exposure increases risk is not understood.
We were concerned that previous immunosuppression might lower total lymphocyte count or the number of CD4+ T-lymphocytes in CSF, which would make our results uninterpretable. Because of inter-laboratory variability in flow cytometry data, we used a central laboratory, with up to 24-h transport time for this critical test. For this study to be valid, we needed to ensure that CSF samples would be stable and results would be interpretable in our patient population. The first part of the study demonstrated that: 1] CSF T-lymphocyte surface markers were stabilised with TransFix ® , a stabilizer for blood lymphocytes, 25, 26 for ≥ 24 h; 2] patients with CD and previous immunosuppressant exposure had CSF lymphocyte counts and subpopulations similar to healthy subjects; and 3] within-subject variability in CSF lymphocyte counts was low enough to evaluate the primary objective.
We then demonstrated that a 12-week induction course of antiMAdCAM-1 monoclonal antibody PF-00547659 did not affect the number or nature of lymphocytes in the CSF. The increase in circulating β7+ central memory T-lymphocytes in PF-00547659-treated patients likely reflects pharmacodynamic activity in drug-mediated reduction of integrin-mediated lymphocyte extravasation into the gut, as previously reported in animal models. 20 A recent publication 27 suggests that vedolizumab treatment may result in accumulation of T-reg cells in the circulation of ulcerative colitis patients, which may limit expansion of T-effector cells in the peripheral blood and favour suppression of systemic inflammation. Natalizumab was the first anti-adhesion molecule to be approved for treatment of patients with CD. As mentioned earlier, its acceptance has been limited by the increased risk of PML, a life-threatening opportunistic infection caused by the John Cunningham virus that attacks the CNS. 6 Natalizumab blocks the α 4 -integrins on leukocytes, which target both MAdCAM-1 and VCAM-1 the gut, and VCAM-1 in the CNS, and therefore can result in profound depression of CSF lymphocytes, especially CD4+ T-lymphocytes. 11 This effect can persist for 6 months after treatment with natalizumab. 28 Interestingly, no case of PML has been reported more than 6 months after cessation of natalizumab therapy unless another immunosuppressive agent was given. 29 The emergence of PML has underscored the importance of CNS immune surveillance of latent JCV reactivation. Previous evidence suggests that VCAM-1 plays a central role in the CNS immune response to viruses. 30 In contrast, our results suggest that MAdCAM-1 does not mediate leukocyte migration into the CNS compartment in patients with CD.
Although MAdCAM-1 is considered mostly gut-selective, it was found to be upregulated in choroid plexus epithelium during experimental autoimmune encephalomyelitis [EAE] , an autoimmune animal model of MS. 19 Monoclonal antibodies against MAdCAM-1 have been shown to effectively prevent the development of actively induced EAE and decrease the number of CNS leukocytes in this model, 31 although conflicting evidence has been reported. 32 It was therefore important to confirm that MAdCAM inhibition would have no impact on CNS lymphocytes.
Vedolizumab, an anti-integrin monoclonal antibody targeted against the α 4 β 7 integrin, is effective in the treatment of IBD. 33, 34 It was the first of the next generation of integrin antibodies with a more selective mode of action-it specifically targets the α 4 β 7 integrin on circulating lymphocytes and blocks its interaction with MAdCAM-1, but does not inhibit α 4 β 1 binding to VCAM-1. Thus, vedolizumab prevents leukocyte migration to the intestinal mucosa. Vedolizumab did not affect T-lymphocyte populations in the CSF of healthy volunteers 5 weeks after a single administration, 35 nor did it inhibit immune surveillance of the CNS in primates. 36 However, the effect of vedolizumab in IBD patients' CNS immune surveillance has not yet been studied.
In conclusion, as measured by the numbers of overall CSF lymphocytes, lymphocyte subsets [CD3+, CD4+, CD8+] and the CD4:CD8 ratio, selective binding of MAdCAM-1 with PF-00547659 does not impair normal CNS immune surveillance in patients with CD and previous immunosuppression, regardless of anti-JC virus antibody seropositivity. Whether the long-term risk of CNS opportunistic infections with high cumulative doses of PF-00547659 is increased cannot be categorically ruled out with the data generated in this study. However, our data provide a good biological rationale to suggest that PF-00547659 treatment of IBD should have a lower risk of PML than do non-selective anti-integrin therapies.
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